NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, News & Analysis

$5.42
+0.33 (+6.48 %)
(As of 09/15/2019 06:15 AM ET)
Today's Range
$5.08
Now: $5.42
$5.49
50-Day Range
$4.34
MA: $4.91
$5.90
52-Week Range
$2.39
Now: $5.42
$6.04
Volume473,406 shs
Average Volume515,118 shs
Market Capitalization$267.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.31
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PIRS
CUSIPN/A
Phone857-246-8998

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.10 million
Book Value$0.74 per share

Profitability

Net Income$-26,750,000.00
Net Margins-147.19%

Miscellaneous

Employees107
Market Cap$267.69 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive PIRS News and Ratings via Email

Sign-up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.


Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) released its quarterly earnings data on Monday, March, 18th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.05. The biotechnology company earned $4.91 million during the quarter, compared to analysts' expectations of $6.92 million. Pieris Pharmaceuticals had a negative return on equity of 114.25% and a negative net margin of 147.19%. View Pieris Pharmaceuticals' Earnings History.

When is Pieris Pharmaceuticals' next earnings date?

Pieris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Pieris Pharmaceuticals.

What price target have analysts set for PIRS?

4 analysts have issued 12 month price objectives for Pieris Pharmaceuticals' shares. Their forecasts range from $5.00 to $7.00. On average, they expect Pieris Pharmaceuticals' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 10.7% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals.

What is the consensus analysts' recommendation for Pieris Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals.

What are Wall Street analysts saying about Pieris Pharmaceuticals stock?

Here are some recent quotes from research analysts about Pieris Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany. " (8/17/2019)
  • 2. William Blair analysts commented, "Wenzel is considered a global expert in the treatment of asthma and has extensive experience in conducting clinical trials in asthma patients, having been a lead author on the Phase II trials of Dupixent (Wenzel et al., 2016) and a co-author in the Phase III pivotal trial. The call reaffirmed that FeNO is a well-validated clinical marker of biological activity in patients with asthma, and our belief that there is a significant market opportunity for PRS-060, an inhaled Anticalin targeting IL-4Rα." (8/16/2019)
  • 3. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and price target of $7. Currently our valuation is based on the three lead assets at the company: (1) PRS-060 for asthma, which is partnered with AstraZeneca contributing 33% of our valuation; (2) PRS-343 for oncology, which currently contributes 39% of our valuation; and (3) PRS-080 for functional iron deficiency anemia contributing 28% of our valuation. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (8/1/2019)

Has Pieris Pharmaceuticals been receiving favorable news coverage?

News headlines about PIRS stock have been trending somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pieris Pharmaceuticals earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Pieris Pharmaceuticals.

Who are some of Pieris Pharmaceuticals' key competitors?

What other stocks do shareholders of Pieris Pharmaceuticals own?

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen S. Yoder, CEO, Pres & Director (Age 43)
  • Dr. Allan Reine, Sr. VP, CFO & Treasurer (Age 44)
  • Dr. Louis A. Matis, Sr. VP & Chief Devel. Officer (Age 68)
  • Mr. Claus Schalper MBA, Co-Founder & Sr. Advisor
  • Maria Kelman, Director of Investor Relations

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.93%), Renaissance Technologies LLC (4.40%), Omega Fund Management LLC (1.53%), Nuveen Asset Management LLC (1.30%), Northern Trust Corp (0.96%) and Vanguard Group Inc. (0.87%). Company insiders that own Pieris Pharmaceuticals stock include Bvf Partners L P/Il, Christopher P Kiritsy, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.

Which institutional investors are selling Pieris Pharmaceuticals stock?

PIRS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Charles Schwab Investment Management Inc., Platinum Investment Management Ltd., Granite Investment Partners LLC, GSA Capital Partners LLP, First Quadrant L P CA, Omega Fund Management LLC and Vanguard Group Inc.. View Insider Buying and Selling for Pieris Pharmaceuticals.

Which institutional investors are buying Pieris Pharmaceuticals stock?

PIRS stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Fosun International Ltd, Renaissance Technologies LLC, Rock Creek Group LP, JPMorgan Chase & Co., Susquehanna International Group LLP, Citadel Advisors LLC and Paloma Partners Management Co. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Christopher P Kiritsy and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $5.42.

How big of a company is Pieris Pharmaceuticals?

Pieris Pharmaceuticals has a market capitalization of $267.69 million and generates $29.10 million in revenue each year. The biotechnology company earns $-26,750,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Pieris Pharmaceuticals employs 107 workers across the globe.View Additional Information About Pieris Pharmaceuticals.

What is Pieris Pharmaceuticals' official website?

The official website for Pieris Pharmaceuticals is http://www.pieris.com/.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]


MarketBeat Community Rating for Pieris Pharmaceuticals (NASDAQ PIRS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  229 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  430
MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe PIRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PIRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/15/2019 by MarketBeat.com Staff

Featured Article: Compound Interest

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel